Media Articles Related to Vantas (Histrelin Implant)
Prostate cancer: Androgen receptor activates different genes when bound to antiandrogens
Source: Endocrinology News From Medical News Today [2015.01.30]
The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...
Drug combo suppresses growth of late-stage prostate cancer tumors
Source: Genetics News From Medical News Today [2015.01.29]
Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study...
High-risk prostate cancers 'better detected' using targeted biopsy
Source: Cancer / Oncology News From Medical News Today [2015.01.28]
Researchers find a targeted biopsy method that combines ultrasound and MRI is more effective for identifying high-risk prostate cancers than the standard biopsy technique.
MRI Improves Prostate Cancer Biopsy Accuracy, Study Finds
Source: MedicineNet Clinical Trials Specialty [2015.01.28]
Title: MRI Improves Prostate Cancer Biopsy Accuracy, Study Finds
Category: Health News
Created: 1/27/2015 12:00:00 AM
Last Editorial Review: 1/28/2015 12:00:00 AM
MR/Ultrasound Biopsy Detects More High-Risk Prostate Cancers
Source: Medscape Hematology-Oncology Headlines [2015.01.27]
Adding MRI to ultrasound-guided biopsy for prostate cancer discovered more high-risk cancers and fewer low-risk cancers.
Medscape Medical News
Published Studies Related to Vantas (Histrelin Implant)
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. [2011.08.18]
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Androgen deprivation therapy with a gonadotropin-releasing hormone agonist is an effective option for the palliative treatment of advanced prostate cancer. This study demonstrated the safety and efficacy of the histrelin acetate implant over successive one year treatment cycles for up to four years in an open-label extension trial. OBJECTIVE: * To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study... CONCLUSIONS: * The once-yearly histrelin implant maintained testosterone suppression for repeated treatment cycles and was generally well tolerated. * The histrelin implant provides a clinically attractive option for long-term androgen deprivation therapy in patients with advanced prostate cancer seeking fewer office visits and repeated injections. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. [2010.08]
CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.
Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. [2010.06]
BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP). The histrelin implant suppresses gonadotropins and estradiol (E(2)) levels for 1 yr, but effects on FAS have not been described. OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion... CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.
Histrelin: in advanced prostate cancer. [2010.03.26]
Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. The subcutaneous histrelin implant provided sustained suppression of serum testosterone, luteinizing hormone (LH) and prostate-specific antigen levels for up to 1 year in patients with advanced prostate cancer in two phase II or III trials...
Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. [2010.01]
Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States... The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.
Clinical Trials Related to Vantas (Histrelin Implant)
Prospective Multicentre Non-interventional Study of VANTASï¿½ for the Treatment of Patients With Advanced Prostate Cancer [Recruiting]
The aim of this non-interventional (observational) study is to document, in collaboration
with established urologists in Scandinavia, experience gained from routine use of Vantas®
for the treatment of patients with advanced prostate cancer. In this observational study
particular attention will be directed to treatment duration, quality of life and patient and
physician acceptance of the medicinal product for long-term therapy. Patient-based
measurement parameters such as quality of life and degree of satisfaction will allow
registration of information that extends beyond the clinical parameters. The knowledge
gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical
outcome will also be documented by measuring serum testosterone and prostate specific
antigen (PSA) levels.
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer [Not yet recruiting]
This randomized phase II trial compares enzalutamide with standard androgen deprivation
therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that
has spread to other places in the body. Metabolic syndrome is defined as changes in
cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies
have shown that patients with prostate cancer, who have been treated with standard medical
therapy that lowers testosterone levels, have an increased risk of these changes. Hormone
therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by
the tumor cells instead of lowering testosterone levels. It is not yet known whether
prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic
syndrome than patients who receive standard androgen deprivation therapy.